drugset / Trial / NCT06016270
A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this clinical study is to assess the safety and efficacy of hSTC810 and paclitaxel combination therapy in patients with relapsed or refractory extensive stage small cell lung cancer.
Timeline
- Start
- 2024-02-13
- Primary completion
- 2025-01-23
- Completion
- 2025-08-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nelmastobart | Monoclonal antibody | 400 mg | Intravenous |
| Subject | Nelmastobart | Monoclonal antibody | 800 mg | Intravenous |
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |